Cargando…
Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments
BACKGROUND: Vaccination against SARS CoV-2 results in excellent personal protection against a severe course of COVID19. In People with Multiple Sclerosis (PwMS) vaccination efficacy may be reduced by immunomodulatory medications. OBJECTIVE: To assess the vaccination induced cellular and humoral immu...
Autores principales: | Bock, H., Juretzek, T., Handreka, R., Ruhnau, J., Löbel, M., Reuner, K., Peltroche, H., Dressel, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783535/ https://www.ncbi.nlm.nih.gov/pubmed/35180617 http://dx.doi.org/10.1016/j.msard.2022.103554 |
Ejemplares similares
-
Lupus and NMOSD: The Blending of Humoral Autoimmunity
por: Ochi, Maria Goretti S., et al.
Publicado: (2020) -
Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
por: Meca-Lallana, Virginia, et al.
Publicado: (2023) -
High-throughput investigation of molecular and cellular biomarkers in NMOSD
por: Yandamuri, Soumya S., et al.
Publicado: (2020) -
Immunomodulatory Effects of Pneumococcal Extracellular Vesicles on Cellular and Humoral Host Defenses
por: Codemo, Mario, et al.
Publicado: (2018) -
Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
por: Adamec, Ivan, et al.
Publicado: (2022)